毒素注射用于逆行式喉功能障碍:一个前性队列研究
Can Doruk1,2, Evan L Kennedy1, Courtney Tipton1
1Center for Voice and Swallowing, Department of Otolaryngology-Head & Neck Surgery, Columbia University Irving Medical Center, New York, New York, U.S.A.
The Laryngoscope
|June 19, 2024
概括
毒素 (BTX) 注射在手术室和办公室环境中有效治疗逆行式喉功能障碍 (RCPD). 虽然这两种方法都能减轻症状和焦虑,但在办公室内注射可能会导致治疗后的消化不良较少.
科学领域:
- 耳鼻喉科 耳鼻喉科 耳鼻喉科
- 胃肠病学 胃肠病学
- 神经学 神经学
背景情况:
- 逆行式喉功能障碍 (RCPD) 是一种疾病,其特点是无法吐和相关的胃肠道症状.
- 毒素 (BTX) 注射到喉肌肉是RCPD的主要治疗方法.
研究的目的:
- 为了比较毒素 (BTX) 注射在手术室 (OR) 和办公室 (IO) 环境中进行的逆行性喉功能障碍 (RCPD) 的有效性和副作用.
- 评估OR与IO BTX注射对RCPD症状,吞功能和焦虑水平的影响.
主要方法:
- 一项前性研究包括18岁以上被诊断患有RCPD的患者,其症状包括无法发,声,胀气和膨胀等症状.
- 患者接受了OR (80U) 或IO (30U) BTX注射.
- 症状严重程度,饮食评估工具-10 (EAT-10) 和通用焦虑评分-7 (GAD-7) 在注射前和在多个随访点评估,直至手术后3个月.
主要成果:
- 治疗后3周和3个月,OR和IO BTX注射都显著降低了RCPD症状和GAD-7得分 (p < 0.0001).
- 在OR和IO组之间没有观察到治疗有效性的显著差异 (p = 0.4924).
- 注射后的EAT-10分数,表明吞困难,在OR组与IO组相比,OR组显著更高 (p = 0.0379).
结论:
- 在手术室和办公室内注射的肉毒素在治疗逆行性喉功能障碍方面表现出相似的疗效.
- 与手术室内注射相比,在办公室内注射可能与治疗后失足症的发病率或严重程度较低有关,这可能是由于BTX剂量较低.
- 用BTX治疗RCPD导致一般焦虑水平的降低.
相关概念视频
01:31Skeletal Muscle Relaxants: Therapeutic Uses
480
Skeletal muscle relaxants are used to relax muscle tone and alleviate painful muscle contractions. However, the choice of skeletal muscle relaxants depends on the duration of the surgical procedure in order to minimize potential side effects. Skeletal muscle relaxants like neuromuscular blocking agents [NMBAs] are commonly employed as adjuvants alongside general anesthetics in clinical settings. NMBAs are also used to maintain controlled ventilation during surgery of the larynx or pharynx...
480
01:19Depolarizing Blockers: Pharmocokinetics
318
Depolarizing blockers are administered through intravenous injection. Succinylcholine is the most common choice of depolarizing blockers in emergency clinical practices. Although they have a rapid onset, they readily diffuse away from the motor end plate into the extracellular fluid. They are metabolized by enzymes such as liver butyrylcholinesterase and plasma pseudocholinesterases. This produces a short duration of action, typically 5-10 minutes long, unlike nondepolarizing blockers, which...
318
01:20Myasthenia Gravis: Overview and Treatment
1.3K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.3K